The Richard M. Schulze Foundation made an equity investment in Bethesda based Northwest Biotherapeutics, Inc.
The microcap biotech received $4.55 million from the foundation on June 28th, 2011.
Currently in Phase III of its leading drug DCVax -Prostate, as the name implies, the treatment was developed as a new way to battle prostate cancer.
Northwest focuses on creating treatments using personalized medicine techniques, the company moved to Montgomery County, Maryland from the Seattle, Washington area in 2007.
